Transplants in Myelodysplastic Syndromes

被引：1

作者：

Wetzko, Katrin ^{[1
]}

Platzbecker, Uwe ^{[1
]}

机构：

[1] TUD, Univ Hosp Carl Gustav Carus, Med Clin 1, D-01307 Dresden, Germany

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2014年 / 28卷 / 06期

关键词：

MDS; Allogeneic HSCT; Relapse; Conditioning; Azacitidine; STEM-CELL TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; BONE-MARROW-TRANSPLANTATION; IDENTICAL SIBLING DONORS; VERSUS-HOST-DISEASE; SCORING SYSTEM; ALLOGENEIC TRANSPLANTATION; INDUCTION CHEMOTHERAPY; RISK MYELODYSPLASIA;

D O I：

10.1016/j.hoc.2014.08.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Myelodysplastic syndromes are one of the most common hematological disorders in the elderly. Therefore, an increase in the prevalence of de novo but also of secondary forms after prior chemotherapy or radiotherapy, respectively, is anticipated within the next years. Allogeneic stem cell transplantation is considered the only potentially curable therapy, but many patients are not eligible because of age or comorbidities. Reduced-intensity conditioning regimens have improved early tolerability of the procedure, although late effects remain a challenge in the care of these patients. However, hypomethylating agents have become available as alternative therapeutic approaches with a moderate toxicity profile.

引用

页码：1011 / +

页数：13

共 50 条

[31] Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission [J].

Martino, R. ;

Valcarcel, D. ;

Brunet, S. ;

Sureda, A. ;

Sierra, J. .

BONE MARROW TRANSPLANTATION, 2008, 41 (01) :33-38

[32] Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT [J].

Martino, R. ;

de Wreede, L. ;

Fiocco, M. ;

van Biezen, A. ;

von dem Borne, P. A. ;

Hamladji, R-M ;

Volin, L. ;

Bornhaeuser, M. ;

Robin, M. ;

Rocha, V. ;

de Witte, T. ;

Kroeger, N. ;

Mohty, M. .

BONE MARROW TRANSPLANTATION, 2013, 48 (06) :761-770

[33] Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia [J].

Platzbecker, U ;

Thiede, C ;

Fuessel, M ;

Geissler, G ;

Illmer, T ;

Mohr, B ;

Hänel, M ;

Mahlberg, R ;

Krümpelmann, U ;

Weissinger, F ;

Schaich, M ;

Theuser, C ;

Ehninger, G ;

Bornhäuser, M .

LEUKEMIA, 2006, 20 (04) :707-714

[34] Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial [J].

Platzbecker, U. ;

Wermke, M. ;

Radke, J. ;

Oelschlaegel, U. ;

Seltmann, F. ;

Kiani, A. ;

Klut, I-M ;

Knoth, H. ;

Roellig, C. ;

Schetelig, J. ;

Mohr, B. ;

Graehlert, X. ;

Ehninger, G. ;

Bornhaeuser, M. ;

Thiede, C. .

LEUKEMIA, 2012, 26 (03) :381-389

[35] Red Blood Cell Transfusion Dependence and Outcome after Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with de Novo Myelodysplastic Syndrome (MDS) [J].

Platzbecker, Uwe ;

Bornhaeuser, Martin ;

Germing, Ulrich ;

Stumpf, Julian ;

Scott, Bart L. ;

Kroeger, Nicolaus ;

Schwerdtfeger, Rainer ;

Boehm, Alexandra ;

Kobbe, Guido ;

Theuser, Catrin ;

Rabitsch, Werner ;

Valent, Peter ;

Sorror, Mohamed L. ;

Ehninger, Gerhard ;

Deeg, H. Joachim .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (11) :1217-1225

[36] Allogeneic Hematopoietic Cell Transplantation in Patients Age 60-70 Years with De Novo High-Risk Myelodysplastic Syndrome or Secondary Acute Myelogenous Leukemia: Comparison with Patients Lacking Donors Who Received Azacitidine [J].

Platzbecker, Uwe ;

Schetelig, Johannes ;

Finke, Juergen ;

Trenschel, Rudolf ;

Scott, Bart L. ;

Kobbe, Guido ;

Schaefer-Eckart, Kerstin ;

Bornhaeuser, Martin ;

Itzykson, Raphael ;

Germing, Ulrich ;

Beelen, Dietrich ;

Ehninger, Gerhard ;

Fenaux, Pierre ;

Deeg, H. Joachim ;

Ades, Lionel .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (09) :1415-1421

[37] Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation [J].

Pollyea, D. A. ;

Artz, A. S. ;

Stock, W. ;

Daugherty, C. ;

Godley, L. ;

Odenike, O. M. ;

Rich, E. ;

Smith, S. M. ;

Zimmerman, T. ;

Zhang, Y. ;

Huo, D. ;

Larson, R. ;

van Besien, K. .

BONE MARROW TRANSPLANTATION, 2007, 40 (11) :1027-1032

[38] Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50 to 75 with Intermediate-2 and High-Risk Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 Study Rationale, Design, and Methods [J].

Saber, Wael ;

Le Rademacher, Jennifer ;

Sekeres, Mikkael ;

Logan, Brent ;

Lewis, Moira ;

Mendizabal, Adam ;

Leifer, Eric ;

Appelbaum, Frederick R. ;

Horowitz, Mary M. ;

Nakamura, Ryotaro ;

Cutler, Corey S. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (10) :1566-1572

[39] Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome [J].

Schmid, C ;

Schleuning, M ;

Ledderose, G ;

Tischer, J ;

Kolb, HJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) :5675-5687

[40] Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation [J].

Schroeder, T. ;

Czibere, A. ;

Platzbecker, U. ;

Bug, G. ;

Uharek, L. ;

Luft, T. ;

Giagounidis, A. ;

Zohren, F. ;

Bruns, I. ;

Wolschke, C. ;

Rieger, K. ;

Fenk, R. ;

Germing, U. ;

Haas, R. ;

Kroeger, N. ;

Kobbe, G. .

LEUKEMIA, 2013, 27 (06) :1229-1235

← 1 2 3 4 5 →